Monitor for potential reverse stock split announcement or capital raise within the next 180 days to avoid delisting. The company's $0.2M cash position makes compliance challenging without immediate financing. Watch for dilutive offerings or warrant exercises as potential compliance mechanisms.
Price Chart
Executive Summary
NeuroSense Therapeutics received two Nasdaq delisting notifications for failing to maintain a $1.00 minimum bid price and $35 million market value of listed securities. The company has until September 29, 2026 to regain compliance. This comes amid severe financial distress with only $0.2 million in cash and no revenue, following transformative clinical data in its lead drug.
Key Facts
- Received Nasdaq notifications for non-compliance with $1.00 minimum bid price rule (Rule 5550(a)(2))
- Received Nasdaq notifications for non-compliance with $35 million market value of listed securities requirement (Rule 5550(b)(2))
- Has until September 29, 2026 (180 days) to regain compliance
- Company market cap is $7 million, far below the $35 million Nasdaq requirement
- Stock currently trading below $1.00 per share
- Prior 20-F filing disclosed only $0.2 million in cash with substantial doubt about going concern
Financial Impact
Company faces potential delisting if it cannot raise capital or execute reverse split by September 29, 2026. Market cap of $7M is $28M below Nasdaq requirement.
Risk Factors
- Potential delisting from Nasdaq if compliance not achieved by September 29, 2026
- Severe liquidity risk with only $0.2 million cash on hand
- Likely need for dilutive capital raise or reverse stock split
- Continued trading on Nasdaq may be suspended if requirements not met
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-039734 |
| Document: ea0285059-6k_neuro.htm | 0001213900-26-039734 |
| Document: 0001213900-26-039734-index-headers.html | 0001213900-26-039734 |
| Document: 0001213900-26-039734-index.html | 0001213900-26-039734 |
| Document: 0001213900-26-039734.txt | 0001213900-26-039734 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 9, 2026 20w ago | 6-K | $0.1451 $0.0500 | ▼ −65.54% | ▼ −69.35% | — |
Jun 8, 2026 20w ago | 6-K | $0.1500 $0.0456 | ▼ −69.60% | ▼ −72.65% | — |
Apr 28, 2026 26w ago | 6-K | $0.2080 $0.0601 | ▼ −71.11% | ▼ −75.10% | — |
Apr 24, 2026 26w ago | 6-K | $0.2080 $0.0811 | ▼ −61.01% | ▼ −66.09% | — |
Apr 6, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▼ −64.76% | ▼ −78.23% | — |
Apr 3, 2026 29w ago | 6-K | $0.2080 $0.0733 | ▲ +64.76% | ▲ +78.23% | — |
Apr 1, 2026 29w ago | 3 | $0.2080 $0.0630 | ▼ −69.71% | ▼ −83.87% | — |
Mar 31, 2026 30w ago | 20-F / 6-K | $0.2080 $0.2080 | · 0.00% | ▼ −13.20% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers